Clene Inc. (CLNN)
CLNN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1822791/000143774926008502/0001437749-26-008502-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CLNN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001822791 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $200K |
| Net income | -$26.2M |
| Operating income | -$23.1M |
| Net margin | -13086.5% |
| Operating margin | -11541.5% |
| Revenue growth | -41.5% |
| Cash | $5.2M |
| Total assets | $18.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 263.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-04 |
| Cash and burn | $9.9M cash; operating cash flow -$4.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 14,400,175 (2026-11-02); 10,333,980 a year earlier; 128,415,605 three years earlier. 3y figure adjusted for split (1-for-20 overall). | Cover page 2026-11-02 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2024-07-11 | Source 2024-07-11 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the market | Latest 2026-09-16 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2025-12-30 |
| Auditor | Deloitte & Touche LLP, Salt Lake City, Utah, United States | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $217K, sold $5.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $56K | $3.9M | -$4.6M | $9.9M | $17.5M | $238K | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $90K | -$13.4M | -$2.6M | $9.7M | $17.6M | $197K | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $15K | -$8.1M | -$4.5M | $5.9M | $17.7M | $134K | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $77K | -$9.2M | -$4.8M | $5.2M | $17.8M | $200K | 10-K 2026-03-17 |
| Q3 2025 2025-09-30 | $15K | -$8.8M | -$4.0M | $7.9M | $17.9M | $214K | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $27K | -$7.4M | -$4.7M | $7.3M | $16.5M | $286K | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $81K | -$751K | -$5.0M | $9.8M | $16.6M | $350K | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $91K | -$13.5M | -$4.9M | $12.2M | $11.2M | $342K | 10-K 2026-03-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2026-09-16 |
| Latest annual report FORM 10-K | 10-K | 2026-03-17 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-04 |
| Latest current report FORM 8-K | 8-K | 2026-11-04 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-04-10 |
Source: SEC EDGAR submissions feed, 715 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.8% |
| 1 month | +15.6% |
| 3 months | -6.4% |
| Year to date | -33.2% |
| 1 year | -46.3% |
| From 52-week high | -62.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| APLM | Apollomics Inc. | $17.84 | +0.91% | $51.7M |
| SDEV | Stablecoin Development Corporation | $0.7055 | -9.55% | $51.6M |
| HRTX | Heron Therapeutics Inc. | $0.2843 | -8.44% | $54.1M |
| XLO | Xilio Therapeutics Inc. | $7.70 | -3.08% | $54.4M |
| QUCY | Quantum Cyber N.V. | $0.5850 | -7.58% | $51.0M |
| AZR | Azora Therapeutics Inc. | $3.81 | -6.85% | $54.4M |
| INCR | Intercure Ltd. | $3.63 | -4.22% | $54.5M |
| CING | Cingulate Inc. | $3.75 | -12.79% | $54.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier